SEARCH

SEARCH BY CITATION

References

  • 1
    Urbich C, Dimmeler S. Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res 2004; 95: 343353.
  • 2
    Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM, Dimmeler S. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003; 108: 25112516.
  • 3
    Bellik L, Ledda F, Parenti A. Morphological and phenotypical characterization of human endothelial progenitor cells in an early stage of differentiation. FEBS Lett 2005; 579: 27312736.
  • 4
    Hristov M, Erl W, Weber PC. Endothelial progenitor cells: Isolation and characterization. Trends Cardiovasc Med 2003; 13: 201206.
  • 5
    Ribatti D. The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med 2004; 8: 294300.
  • 6
    Asahara T, Masuda H, Takahashi T et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221228.
  • 7
    Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004; 104: 20732080.
  • 8
    Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335340.
  • 9
    Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 19261945.
  • 10
    Fingar DC, Blenis J. Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23: 31513171.
  • 11
    Riesterer O, Zingg D, Hummerjohann J, Bodis S, Pruschy M. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene 2004; 23: 46244635.
  • 12
    Kahan BD, Camardo JS. Rapamycin: Clinical results and future opportunities. Transplantation 2001; 72: 11811193.
  • 13
    Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847858.
  • 14
    Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 17731780.
  • 15
    Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 2003; 3: 371377.
  • 16
    Kalka C, Masuda H, Takahashi T et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000; 86: 11981202.
  • 17
    Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000; 105: 7177.
  • 18
    Stengel D, Antonucci M, Gaoua W et al. Inhibition of LPL expression in human monocyteûderived macrophages is dependent on LDL oxidation state: A key role for lysophosphatidylcholine. Arterioscler Thromb Vasc Biol 1998; 18: 11721180.
  • 19
    William R, Watson G, Rotstein OD, Parodo J, Bitar R, Marshall JC. The IL-1{beta}-converting enzyme (Caspase-1) inhibits apoptosis of inflammatory neutrophils through activation of IL-1{beta}. J Immunol 1998; 161: 957962.
  • 20
    Munafo DB, Colombo MI. A novel assay to study autophagy: Regulation of autophagosome vacuole size by amino acid deprivation. J Cell Sci 2001; 114: 36193629.
  • 21
    U.S. Food and Drug Administration. CYPHER™: Summary of safety and effectiveness. http://www.fda.gov/cdrh/PDF2/P020026b.PDF. 2003.
  • 22
    Sugatani T, Hruska KA. Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 2005; 280: 35833589.
  • 23
    Woltman AM, Van Der Kooij SW, Coffer PJ, Offringa R, Daha MR, Van Kooten C. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003; 101: 14391445.
  • 24
    Desai BN, Myers BR, Schreiber SL. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc Natl Acad Sci U S A 2002; 99: 43194324.
  • 25
    Thyrell L, Hjortsberg L, Arulampalam V et al. Interferon {alpha}-induced apoptosis in tumor cells is mediated through the phosphoinositide 3-kinase/mammalian target of rapamycin signaling pathway. J Biol Chem 2004; 279: 2415224162.
  • 26
    Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci U S A 2001; 98: 96669670.
  • 27
    Shinjyo T, Kuribara R, Inukai T et al. Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol 2001; 21: 854864.
  • 28
    Wendel HG, De Stanchina E, Fridman JS et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332337.
  • 29
    Cuervo AM. Autophagy: Many paths to the same end. Mol Cell Biochem 2004; 263: 5572.
  • 30
    Levine B, Yuan J. Autophagy in cell death: An innocent convict? J Clin Invest 2005; 115: 26792688.
  • 31
    Ravikumar B, Stewart A, Kita H, Kato K, Duden R, Rubinsztein DC. Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophagy. Hum Mol Genet 2003; 12: 985994.
  • 32
    Gerber HP, Malik AK, Solar GP et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954958.
  • 33
    Butzal M, Loges S, Schweizer M et al. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res 2004; 300: 6571.
  • 34
    Fukuda D, Sata M, Tanaka K, Nagai R. Potent inhibitory effect of sirolimus on circulating vascular progenitor cells. Circulation 2005; 111: 926931.
  • 35
    Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005; 111: 22572273.